KALA BIO, Inc. - KALA STOCK NEWS

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company specializing in innovative eye disease therapies, will present at the BofA Securities 2021 Healthcare Conference. The management team is set to participate in a Fireside Chat on May 13, 2021, at 4:15 pm ET. Investors can access the live webcast and a recording afterward via the 'Events' section of the Kala website. The company's products include EYSUVIS® and INVELTYS®, which utilize AMPPLIFY® technology, addressing dry eye disease and post-operative inflammation.

Kala Pharmaceuticals (NASDAQ:KALA) reported its Q1 2021 financial results, highlighting a net loss of $30.4 million or $0.49 per share, versus a $22 million loss in Q1 2020. Product revenues reached $3.3 million, driven by EYSUVIS and INVELTYS sales. The company has secured coverage for approximately 43% of commercial lives and plans to expand its sales force from 91 to 125 by year-end. A new credit facility of up to $125 million was established to extend cash runway for at least two years. The company continues to progress its pipeline for treating eye diseases.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will announce its first quarter 2021 financial results on May 5, 2021. A conference call will follow at 8:00 a.m. ET to discuss results and provide a business update. Dial-in numbers are 866-300-4091 (domestic) and 703-736-7433 (international) with conference ID 2777865. The company focuses on innovative therapies for eye diseases, utilizing its AMPPLIFY® drug delivery technology in products like EYSUVIS® for dry eye and INVELTYS® for postoperative inflammation. Visit kalarx.com for more information.

Kala Pharmaceuticals (NASDAQ: KALA) announced the granting of stock options to four new employees as part of inducement awards outside the Company’s 2017 Equity Incentive Plan, in line with NASDAQ Rule 5635(c)(4). The options, totaling 32,200 shares, were granted on March 15, 2021, with an exercise price set at $7.54 per share, coinciding with the closing stock price on that date. These options have a ten-year term, vesting over four years, subject to each employee's continued service.

Kala Pharmaceuticals (NASDAQ:KALA) announced that Cigna has added its product EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% to its commercial formulary as a preferred brand, effective May 15, 2021. This addition is expected to enhance patient access to EYSUVIS, which is the first prescription drug approved for the short-term treatment of dry eye disease symptoms. The company aims to engage with additional health plans to expand coverage for this therapy, enhancing its market presence.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will participate in two virtual healthcare investor conferences in March 2021. The H.C. Wainwright Global Life Sciences Conference is scheduled for March 9-10, featuring a pre-recorded presentation available on March 9 at 7:00 am ET. The Oppenheimer 31st Annual Healthcare Conference will follow on March 16 at 3:50 pm ET with a fireside chat. Interested parties can access recordings on Kala's website under the 'Events' section.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) reported financial results for Q4 and full year 2020, emphasizing a pivotal year with FDA approval of EYSUVIS for dry eye disease. The company achieved $2.2 million in net product revenues for Q4, with $1.9 million from INVELTYS and $0.3 million from EYSUVIS. Despite increasing revenues, net loss for Q4 was $31.1 million and full year loss was $104.3 million. Kala has a strong cash position of $153.5 million as of Dec 31, 2020, allowing continued investment in pipeline programs addressing various ocular diseases.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will announce its fourth quarter and full year 2020 financial results on February 25, 2021. A conference call will be held at 8:00 a.m. ET to discuss these results and provide a business update. Shareholders can use dial-in numbers 866-300-4091 (domestic) or 703-736-7433 (international) with conference ID 5865513. Kala is known for its innovative therapies for eye diseases, including EYSUVIS™ and INVELTYS™, and has ongoing pre-clinical development programs targeting key medical needs.

Kala Pharmaceuticals (NASDAQ:KALA) announced the grant of non-statutory stock options to two new employees totaling 16,500 shares. The options, issued on February 12, 2021, have an exercise price of $8.63 per share, equal to the stock's closing price on that date. The vesting schedule allows for 25% to vest after one year, with the remainder vesting monthly over three years, contingent on continued employment. This move aligns with NASDAQ Listing Rule 5635(c)(4) to attract new talent.